A randomized, double-blind simulator study of 38 adults found that vaporized cannabis impaired driving performance for up to 5.5 hours after use, far longer than the three-hour window most prior research examined. Critically, about two-thirds of participants said they would be willing to drive even while objectively impaired, and blood THC levels did not reliably predict who was driving poorly.

As cannabis legalization continues to expand across the United States and globally, clinicians who recommend or prescribe cannabis-based therapies urgently need evidence-based guidance on how long their patients should wait before driving. Most prior research examined impairment only within the first three hours after dosing, leaving a dangerous blind spot in safety counseling. This study’s finding that impairment extends well beyond that window, coupled with the revelation that users consistently overestimate their own fitness to drive, creates an immediate imperative for clinicians to revise the safety guidance they provide to patients.

Cannabis-impaired driving is one of the most consequential public safety questions in cannabis medicine, yet the evidence base for how long impairment actually lasts has remained surprisingly thin. Most prior simulator and on-road studies measured outcomes only at one or two time points within three hours of dosing, making it impossible to know when users genuinely return to baseline. This randomized, double-blind, placebo-controlled crossover study sought to close that gap by testing 38 licensed-driver adults across a full eight-hour assessment day after vaporizing 0.5 grams of cannabis at either 5.9% THC (approximately 29.5 mg), 13% THC (approximately 65 mg), or placebo. Participants completed simulated lane-keeping, car-following, and overtaking tasks at four distinct time points throughout each session.

The results showed dose-dependent impairment that persisted far longer than expected. Lane-keeping deterioration, measured by reduced steering reversal rate, lasted up to 5.5 hours at the higher dose and 3.5 hours at the lower dose. The 13% THC condition also produced riskier overtaking behavior, including shorter gaps to passed vehicles, lower time-to-potential collision, and more time spent in the oncoming lane. Perhaps most troubling, approximately 66% of participants reported they would be willing to drive even while acknowledging subjective impairment and demonstrating objectively worse performance. Blood THC and metabolite concentrations showed no meaningful correlation with driving outcomes, undermining the premise that blood-draw thresholds can serve as reliable standalone impairment markers. The authors emphasize that this is a pilot study with a modest sample size skewed heavily toward frequent users (89.5%), and they call for replication in larger, more diverse cohorts that include occasional users.

This study gets something fundamentally right: it asks the question that matters most to my patients and to public safety. Three hours has never felt like an adequate waiting period to me clinically, and now there is rigorous preliminary evidence confirming that instinct. The finding that blood THC levels do not track with actual impairment is also critically important. It suggests that the legal frameworks being built around per se blood THC limits in several states may be scientifically unjustified, at least when applied as the sole measure of fitness to drive.

In my practice, I already counsel patients who use inhaled cannabis to avoid driving for a minimum of four to six hours after use, and I discuss with them that their subjective sense of being “fine” is not a reliable indicator. This study reinforces that approach. I also remind patients that edibles, which were not tested here, almost certainly extend the impairment window further. The bottom line I share with every cannabis patient is simple: if you would not drive after two glasses of wine, do not drive after vaping cannabis, and give yourself considerably more time than you think you need.

This study sits at a pivotal point in the research arc on cannabis and driving. Prior simulator work, including the landmark studies by Hartman and colleagues and the meta-analyses by Rogeberg and Elvik, established that acute cannabis use impairs driving but generally assessed outcomes within a narrow post-dose window. This crossover design extends the observation period to eight hours and provides the first structured evidence that lane-keeping impairment at moderate THC doses persists well into the fifth and sixth hours. For clinicians advising medical cannabis patients, this represents a meaningful shift in what can be communicated with evidence rather than intuition alone. However, the predominantly frequent-user sample (89.5%) means the findings may actually underestimate impairment in occasional users, who typically show greater sensitivity to THC’s psychomotor effects.

From a pharmacological standpoint, clinicians should note that the study used vaporized flower, which produces a rapid-onset, relatively predictable kinetic profile compared to oral or sublingual preparations. Edible cannabis products, which produce delayed peak blood levels and prolonged pharmacodynamic effects, would likely extend the impairment duration beyond the 5.5-hour mark observed here. Drug interaction considerations also apply: patients concurrently using benzodiazepines, opioids, antihistamines, or other sedating medications should be counseled that add

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care